In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulse Biosciences Inc. (NASDAQ:PLSE) reported that Duggan Robert W has picked up 2,578,950 of common stock as of 2017-04-11.

The acquisition brings the aggregate amount owned by Duggan Robert W to a total of 2,578,950 representing a 18.2% stake in the company.

For those not familiar with the company, Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

A glance at Pulse Biosciences Inc. (NASDAQ:PLSE)’s key stats reveals a current market capitalization of 351.73 Million based on 14.14 Million shares outstanding and a price at last close of $23.18 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-10, Duggan picked up 22,764 at a purchase price of $21.40. This brings their total holding to 2,578,950 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulse Biosciences Inc. (NASDAQ:PLSE) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.